Cardiff Oncology, Inc. (CRDF) shareholders
Close on Nov 20, 2026Market cap $66.34MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of CRDF | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Laurion Capital Management LP | 3,098,299 | 3.98% | $4.03M | +451,561 | 0.10% |
| Vanguard Capital Management LLC | 2,895,592 | 3.72% | $3.76M | +39,626 | 0.00% |
| Pfizer Inc | 2,411,575 | 3.10% | $3.01M | – | 1.77% |
| Franklin Resources Inc | 1,205,803 | 1.55% | $1.57M | – | 0.00% |
| BlackRock, Inc. | 972,873 | 1.25% | $1.26M | −3,008,514 | 0.00% |
| Blair William & Co/Il | 912,513 | 1.17% | $1.19M | −9,894 | 0.00% |
| Geode Capital Management, LLC | 820,062 | 1.05% | $1.07M | −779,601 | 0.00% |
| UBS Group AG | 638,699 | 0.82% | $830.31K | +238,123 | 0.00% |
| Jane Street Group, LLC | 607,900 | 0.78% | $790.27K | +567,795 | 0.00% |
| Vanguard Fiduciary Trust Co | 410,602 | 0.53% | $533.78K | −35,623 | 0.00% |
| Aqr Capital Management LLC | 346,353 | 0.45% | $450.26K | +280,197 | 0.00% |
| State Street Corp | 331,395 | 0.43% | $430.81K | −855,552 | 0.00% |
| Hrt Financial LP | 272,786 | 0.35% | $354.00K | New | 0.00% |
| Flputnam Investment Management Co | 247,474 | 0.32% | $321.72K | −347,653 | 0.00% |
| Morgan Stanley | 246,095 | 0.32% | $319.92K | +189,789 | 0.00% |
| Bnp Paribas Arbitrage, Snc | 228,461 | 0.29% | $297.00K | +215,385 | 0.00% |
| X-Square Capital, LLC | 205,700 | 0.26% | $267.00K | New | 0.07% |
| Gsa Capital Partners Llp | 173,274 | 0.22% | $225.00K | +50,266 | 0.01% |
| Marshall Wace, Llp | 162,214 | 0.21% | $210.88K | New | 0.00% |
| Bank of New York Mellon Corp | 161,689 | 0.21% | $210.20K | −141,739 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 104 | 19M | 24.2% | 20 / 35 | 26 / 31 | 3M | 9M |
| Q1 2026 | 117 | 25M | 31.6% | 23 / 30 | 37 / 14 | 5M | 4M |
| Q4 2025 | 110 | 27M | 35.0% | 17 / 25 | 34 / 18 | 4M | 2M |
| Q3 2025 | 112 | 25M | 32.4% | 19 / 33 | 29 / 20 | 3M | 7M |
| Q2 2025 | 114 | 29M | 37.1% | 18 / 45 | 23 / 19 | 6M | 9M |
| Q1 2025 | 116 | 32M | 41.6% | 17 / 49 | 17 / 17 | 8M | 3M |
| Q4 2024 | 117 | 28M | 36.1% | 37 / 39 | 17 / 3 | 17M | 1M |
| Q3 2024 | 83 | 13M | 16.4% | 9 / 25 | 24 / 15 | 4M | 2M |
| Q2 2024 | 90 | 13M | 16.9% | 29 / 33 | 12 / 16 | 7M | 2M |
| Q1 2024 | 77 | 9M | 11.3% | 28 / 17 | 10 / 6 | 4M | 0M |
| Q4 2023 | 55 | 5M | 6.8% | 7 / 9 | 13 / 7 | 0M | 0M |
| Q3 2023 | 55 | 5M | 6.9% | 7 / 8 | 15 / 4 | 0M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
95 funds held CRDF in Q1 2026, 66% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of CRDF | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2,073,126 | 2.66% | $2.70M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 759,321 | 0.98% | $987.12K | 0.00% | Jun 30, 2026 |
| Franklin Biotechnology Discovery Fund | 438,961 | 0.56% | $375.49K | 0.03% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 363,388 | 0.47% | $690.44K | 0.00% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 324,898 | 0.42% | $617.31K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 221,689 | 0.28% | $288.20K | 0.02% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 114,137 | 0.15% | $216.86K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 100,743 | 0.13% | $191.41K | 0.00% | May 31, 2026 |
| Small Company Growth Portfolio | 72,057 | 0.09% | $93.67K | 0.01% | Jun 30, 2026 |
| Goldman Sachs Absolute Return Tracker Fund | 46,242 | 0.06% | $60.11K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 35,418 | 0.05% | $46.04K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 34,646 | 0.04% | $65.83K | 0.00% | May 31, 2026 |
| Fidelity ZERO Total Market Index Fund | 30,591 | 0.04% | $26.17K | 0.00% | Jul 31, 2026 |
| Vanguard Russell 2000 Growth Index Fund | 28,295 | 0.04% | $53.76K | 0.00% | May 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 27,727 | 0.04% | $36.05K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Mani Mohindru | Chief Executive Officer, Director | 59,067 | 0.08% | Jul 16, 2026 |
| Mark Erlander | Chief Executive Officer, Director | 24,481 | 0.03% | Mar 13, 2025 |
| Leila Alland | Chief Medical Officer | – | – | Oct 27, 2026 |
| Ajay Aggarwal | Chief Operating Officer | – | – | Apr 28, 2026 |
| Tod Smeal | Chief Scientific Officer | – | – | Apr 16, 2026 |
| Joshua B. Muntner | Chief Financial Officer | 500 | 0.00% | Apr 16, 2026 |
| Brigitte Ute Lindsay | Chief Accounting Officer | 27,431 | 0.04% | Feb 18, 2026 |
| Roger Sidhu | Chief Medical Officer | – | – | Jul 8, 2025 |
| Fairooz Kabbinavar | Chief Medical Officer | – | – | Mar 13, 2025 |
| James E. Levine | Chief Financial Officer | 127,716 | 0.16% | Mar 13, 2025 |
| Gary W. Pace | Director | 3,389,337 | 4.36% | Jul 16, 2026 |
| Renee P. Tannenbaum | Director | 20,000 | 0.03% | Jun 15, 2026 |
| James O. Armitage | Director | 27,490 | 0.04% | Jun 15, 2026 |
| Lale White | Director | 113,788 | 0.15% | Jun 15, 2026 |
| Rodney S. Markin | Director | 31,060 | 0.04% | Jun 15, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mani Mohindru Chief Executive Officer, Director | Jul 14, 2026 | Buy | +34,364 | $1.46 | $50.17K | 59,067 |
| Gary W. Pace Director | Jul 14, 2026 | Buy | +687,285 | $1.46 | $1.00M | 2,043,661 |
| Gary W. Pace Director | Jun 18, 2026 | Buy | +30,000 | $1.22 | $36.60K | 1,356,376 |
| Mani Mohindru Chief Executive Officer, Director | Jun 18, 2026 | Buy | +24,703 | $1.21 | $29.89K | 24,703 |
| Gary W. Pace Director | Jul 30, 2025 | Buy | +15,000 | $2.45 | $36.75K | 1,345,676 |
| Gary W. Pace Director | Jul 30, 2025 | Buy | +275,000 | $2.45 | $673.75K | 1,330,676 |
| James E. Levine Chief Financial Officer | Dec 18, 2024 | Buy | +2,400 | $5.00 | $12.00K | 67,716 |
| James E. Levine Chief Financial Officer | Dec 17, 2024 | Buy | +2,752 | $5.42 | $14.92K | 65,316 |
| James E. Levine Chief Financial Officer | Dec 16, 2024 | Buy | +2,564 | $3.83 | $9.82K | 62,564 |
| Renee P. Tannenbaum Director | Dec 12, 2024 | Buy | +10,000 | $3.42 | $34.20K | 20,000 |
| Gary W. Pace Director | Dec 11, 2024 | Buy | +350,115 | $2.60 | $910.30K | 1,047,876 |
| Gary W. Pace Director | Dec 11, 2024 | Buy | +11,500 | $2.60 | $29.90K | 1,059,376 |
| Gary W. Pace Director | Dec 19, 2023 | Buy | +30,000 | $1.37 | $41.10K | 697,761 |
| Gary W. Pace Director | Nov 10, 2023 | Buy | +22,950 | $0.98 | $22.49K | 667,761 |
| Mark Erlander Chief Executive Officer, Director | Nov 25, 2022 | Buy | +10,000 | $1.43 | $14.30K | 24,481 |
| Lale White Director | Sep 19, 2022 | Buy | +15,000 | $1.64 | $24.60K | 113,788 |
| James O. Armitage Director | Sep 16, 2022 | Buy | +13,000 | $1.56 | $20.28K | 13,000 |
| James E. Levine Chief Financial Officer | Sep 16, 2022 | Buy | +30,000 | $1.56 | $46.80K | 60,000 |
| Renee P. Tannenbaum Director | Sep 15, 2022 | Buy | +3,600 | $1.72 | $6.19K | 10,000 |
| Renee P. Tannenbaum Director | Sep 15, 2022 | Buy | +6,400 | $1.72 | $11.01K | 6,400 |
| Gary W. Pace Director | Sep 15, 2022 | Buy | +150,000 | $1.71 | $256.50K | 644,811 |
| Lale White Director | Jul 5, 2022 | Option exercise | +28,858 | $2.60 | $75.03K | 98,788 |
| Gary W. Pace Director | Sep 21, 2021 | Buy | +30,000 | $6.75 | $202.50K | 494,811 |
| James E. Levine Chief Financial Officer | Sep 10, 2021 | Buy | +5,000 | $6.32 | $31.60K | 30,000 |
| James E. Levine Chief Financial Officer | Sep 10, 2021 | Buy | +5,000 | $6.35 | $31.75K | 25,000 |
| James E. Levine Chief Financial Officer | Sep 10, 2021 | Buy | +10,000 | $6.38 | $63.80K | 20,000 |
| James E. Levine Chief Financial Officer | Sep 10, 2021 | Buy | +5,000 | $6.75 | $33.75K | 10,000 |
| James E. Levine Chief Financial Officer | Sep 10, 2021 | Buy | +5,000 | $6.62 | $33.10K | 5,000 |
| Rodney S. Markin Director | Mar 26, 2021 | Buy | +2,900 | $10.32 | $29.93K | 23,879 |
| Gary W. Pace Director | Mar 23, 2021 | Buy | +5,000 | $10.20 | $51.00K | 459,811 |
| Gary W. Pace Director | Mar 23, 2021 | Buy | +2,500 | $10.31 | $25.78K | 464,811 |
| Gary W. Pace Director | Mar 23, 2021 | Buy | +2,500 | $10.21 | $25.53K | 462,311 |
| Vicki Kelemen Exec. VP and COO | Mar 23, 2021 | Buy | +960 | $10.31 | $9.90K | 6,053 |
| Gary S. Jacob Director | Mar 23, 2021 | Buy | +1,900 | $10.42 | $19.80K | 21,452 |
| Gary S. Jacob Director | Mar 23, 2021 | Buy | +470 | $10.40 | $4.89K | 21,922 |
| Mark Erlander Chief Executive Officer | Mar 23, 2021 | Buy | +965 | $10.34 | $9.98K | 14,481 |
| John P. Brancaccio Director | Mar 22, 2021 | Buy | +3,000 | $10.95 | $32.85K | 12,260 |
| James O. Armitage Director | Mar 19, 2021 | Buy | +4,000 | $10.82 | $43.28K | 14,490 |
| Gary W. Pace Director | Mar 18, 2021 | Buy | +2,000 | $10.54 | $21.08K | 454,811 |
| Gary W. Pace Director | Mar 18, 2021 | Buy | +1,000 | $10.58 | $10.58K | 452,811 |
| Gary W. Pace Director | Mar 4, 2021 | Buy | +1,500 | $9.27 | $13.91K | 451,811 |
| Mark Erlander Chief Executive Officer | Jan 2, 2021 | Tax withholding | −113 | – | – | 13,516 |
| Mark Erlander Chief Executive Officer | Jan 2, 2021 | Option exercise | +260 | – | – | 13,629 |
| Vicki Kelemen Exec. VP and COO | Jan 2, 2021 | Tax withholding | −31 | – | – | 5,093 |
| Vicki Kelemen Exec. VP and COO | Jan 2, 2021 | Option exercise | +70 | – | – | 5,124 |
| Vicki Kelemen Exec. VP and COO | Nov 23, 2020 | Sale | −35,321 | $18.60 | $656.97K | 5,054 |
| Vicki Kelemen Exec. VP and COO | Nov 23, 2020 | Option exercise | +35,321 | $2.48 | $87.60K | 40,375 |
| Gary W. Pace Director | Sep 16, 2020 | Buy | +1,700 | $5.69 | $9.67K | 449,461 |
| Gary W. Pace Director | Sep 16, 2020 | Buy | +850 | $5.71 | $4.85K | 450,311 |
| James O. Armitage Director | May 14, 2020 | Buy | +10,490 | $1.43 | $15.00K | 10,490 |
| Mark Erlander Chief Executive Officer | May 14, 2020 | Buy | +6,993 | $1.43 | $10.00K | 13,369 |
| Rodney S. Markin Director | May 14, 2020 | Buy | +20,979 | $1.43 | $30.00K | 28,160 |
| Lale White Director | May 14, 2020 | Buy | +69,930 | $1.43 | $100.00K | 69,930 |
| John P. Brancaccio Director | May 14, 2020 | Buy | +6,993 | $1.43 | $10.00K | 9,260 |
| Gary S. Jacob Director | May 14, 2020 | Buy | +17,483 | $1.43 | $25.00K | 19,552 |
| Thomas Adams Phd Director | May 14, 2020 | Buy | +13,986 | $1.43 | $20.00K | 18,875 |
| Gary W. Pace Director | May 11, 2020 | Buy | +447,761 | $1.34 | $600.00K | 447,761 |
| Mark Erlander Chief Scientific Officer | Jan 3, 2020 | Tax withholding | −116 | – | – | 6,376 |
| Mark Erlander Chief Scientific Officer | Jan 3, 2020 | Tax withholding | −552 | – | – | 6,231 |
| Mark Erlander Chief Scientific Officer | Jan 2, 2020 | Option exercise | +261 | – | – | 6,492 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Cardiff Oncology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 37,995 shares on Aug 25, 2026 over the last 90 days.
See a number that looks wrong?